MetaADEDB 2.0 @ LMMD
Cinnarizine
(DERZBLKQOCDDDZ-JLHYYAGUSA-N)
Structure
SMILES
c1ccc(cc1)/C=C/CN1CCN(CC1)C(c1ccccc1)c1ccccc1
Type(s)
Approved; Investigational
ATC code(s)
N07CA02; N07CA52
Molecular Formula:
C26H28N2
Molecular Weight:
368.514
Log P:
4.9828
Hydrogen Bond Acceptor:
2
Hydrogen Bond Donor:
0
TPSA:
6.48
CAS Number(s):
298-57-7; 16699-20-0
Synonym(s)
1.
Cinnarizine
2.
1-(Diphenylmethyl)-4-(3-phenyl-2-propenyl)piperazine
3.
Cinarizina Inkey
4.
Cinarizina Ratiopharm
5.
Cinarizine
6.
Cinazière
7.
Cinna
8.
Cinnarizin AL
9.
Cinnarizin Siegfried
10.
Cinnarizin Von Ct
11.
Cinnarizin-Ratiopharm
12.
Cinnarizine L-Tartrate
13.
Cinnarizine L-Tartrate (1:1)
14.
Cinnarizine, (E)-Isomer
15.
Cinnarizine, Dihydrochloride
16.
Cinnipirine
17.
Cisaken
18.
Dimitronal
19.
R-516
20.
Stugeron
21.
Stugeron Forte
22.
Cinnarizin Ratiopharm
23.
Cinnarizine L Tartrate
24.
Dihydrochloride Cinnarizine
25.
L-Tartrate, Cinnarizine
26.
R 516
27.
R516
28.
Von Ct, Cinnarizin
External Link(s)
MeSHD002936
PubChem Compound1547484
2761
BindingDB50017657
ChEBI31403
131176
CHEMBLCHEMBL43064
DrugBankDB00568
DrugCentral654
IUPHAR/BPS Guide to PHARMACOLOGY9072
KEGGdr:D01295
Therapeutic Target DatabaseD0Q3YO
ZINC19632891
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1AcidosisOFFSIDES
2AgoraphobiaOFFSIDES
3Akathisia, Drug-Induced10390751CTD
4Alanine Aminotransferase IncreasedOFFSIDES
5Alcohol consumptionOFFSIDES
6AmnesiaOFFSIDES
7ApathyOFFSIDES
8AsphyxiaOFFSIDES
9Asthenia10190745CTD
10AsthmaOFFSIDES
11Basal Ganglia Diseases2703850
10390751		CTD
12Bipolar I disorderOFFSIDES
13Blepharospasm16855418CTD
14Blood creatine phosphokinase increasedOFFSIDES
15Blood glucose decreasedOFFSIDES
16Blood glucose fluctuationOFFSIDES
17Blurred visionOFFSIDES
18Bone erosionOFFSIDES
19Bone painOFFSIDES
20Brain Diseases3574697CTD
21Capillary FragilityOFFSIDES
22Catalepsy11180191CTD
23Cervical polypOFFSIDES
24Chemical and Drug Induced Liver Injury10190745CTD
25Cholecystolithiasis10190745CTD
26Cholestasis2271847
10190745		CTD
27Cold sweatOFFSIDES
28ConfabulationOFFSIDES
29Depressed Level of ConsciousnessOFFSIDES
30Depressed moodOFFSIDES
31Depressive disorder

View details

2733706
3147743
10390751
15476069
 		CTD
32Disease recurrenceOFFSIDES
33Dizziness2271847CTD
OFFSIDES
34Drug ineffectiveOFFSIDES
35Drug toxicityOFFSIDES
36Dysthymic DisorderOFFSIDES
37DysuriaOFFSIDES
38Emotional disorderOFFSIDES
39Eustachian tube disorderOFFSIDES
40HomicideOFFSIDES
41Intentional self-injuryOFFSIDES
42Kidney FailureOFFSIDES
43LethargyOFFSIDES
44Lupus Erythematosus, Cutaneous9696142CTD
45Movement Disorders2733706CTD
46Negative thoughtsOFFSIDES
47NephrolithiasisOFFSIDES
48Optic AtrophyOFFSIDES
49OverdoseOFFSIDES
50Parkinson Disease3351524CTD
51Performance status decreasedOFFSIDES
52Physical assaultOFFSIDES
53Pneumocystis jiroveci pneumoniaOFFSIDES
54Prothrombin time abnormalOFFSIDES
55Pruritus10190745CTD
56RhinalgiaOFFSIDES
57Seizures1242663CTD
58Tremor3147743CTD
59Ventricular Fibrillation575496CTD
60Vertigo

View details

3574697
10390751
15262457
16855418
 		CTD
61Vestibular Diseases15262457CTD
62Weight GainOFFSIDES
63jaundice10190745CTD
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120235

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.